Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
John D HeissCodrin LunguDima A HammoudPeter HerscovitchDebra J EhrlichDavis P ArgersingerSanhita SinharayGretchen ScottTianxia WuHoward J FederoffKareem A ZaghloulMark HallettRussell R LonserKrystof S BankiewiczPublished in: Movement disorders : official journal of the Movement Disorder Society (2019)
Adeno-associated virus, serotype-2 vector carrying glial cell line-derived neurotrophic factor infusion was safe and well tolerated. Increased [18 F]FDOPA uptake suggests a neurotrophic effect on dopaminergic neurons. © 2019 International Parkinson and Movement Disorder Society.
Keyphrases
- magnetic resonance
- study protocol
- spinal cord
- clinical trial
- low dose
- dengue virus
- copy number
- phase iii
- genome wide
- neuropathic pain
- disease virus
- phase ii
- gene therapy
- klebsiella pneumoniae
- escherichia coli
- genome wide identification
- gene expression
- magnetic resonance imaging
- computed tomography
- transcription factor
- multidrug resistant
- open label